Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells

Benjamin Kroger, Roni Tamari, Carmelo Gurnari, Julio Alvarenga Thiebaud, Alejandro Marinos Velarde, Yazan F Madanat, Robert H. Collins, Clayton Jackson, Vivian Irizarry Gatell, Valeria Visconte, Jaroslaw Maciejewski, David Sallman, Stephen Chung

Blood (2024) 144 (Supplement 1): 777.

https://doi.org/10.1182/blood-2024-212380

Published: 2024

Journal Articles

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 737.

https://doi.org/10.1182/blood-2024-207953

Published: 2024

Journal Articles

Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

Katherine Tobon, Kylie Consalvo, Syeda Saba Kareem, Jeffrey E Lancet, Rami S. Komrokji, Javier Pinilla-Ibarz, David Sallman, Jennifer Eatrides, Alison R. Walker, Julio C. Chavez, Leidy Lismeris Isenalumhe, Bijal D Shah

Blood (2024) 144 (Supplement 1): 2820.

https://doi.org/10.1182/blood-2024-201486

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes

David Sallman, Amy F McLemore, Rami S. Komrokji, Hany Elmariah, Andrew T. Kuykendall, Nelli Bejanyan, Onyee Chan, Rawan Faramand, Joseph A. Pidala, Sean J. Yoder, Lia Perez, Taiga Nishihori, Eric Padron, Hugo Francisco Fernandez, Jeffrey E Lancet, Asmita Mishra

Blood (2024) 144 (Supplement 1): 1046.

https://doi.org/10.1182/blood-2024-203903

Published: 2024

Journal Articles

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Somedeb Ball, Najla H. Al Ali, Akriti G. Jain, Moazzam Shahzad, Junmin Whiting, Daniel Lastorino, Zhuoer Xie, Alison R. Walker, Onyee Chan, Eric Padron, Jongphil Kim, Jeffrey E Lancet, David Sallman, Sara M. Tinsley-Vance, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 532.

https://doi.org/10.1182/blood-2024-209273

Published: 2024

Journal Articles

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall, Tania Jain, Abhay Singh, Kristen M. Pettit, Quan Lovette, Joan McFadden Cain, Tracy Ann Cinalli, Mary Gallagher, David Sallman, Qianxing Mo, Ling Zhang, Onyee Chan, Alison R. Walker, Zhuoer Xie, Jeffrey E Lancet, Maria Balasis, Seongseok Yun, Eric Padron, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 481.

https://doi.org/10.1182/blood-2024-210743

Published: 2024

Journal Articles

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

Zhuoer Xie, Zena Komrokji, Michael Otterstatter, Ling Zhang, Lynn C. Moscinski, Najla H. Al Ali, David Sallman, Jeffrey E Lancet, Amy E. DeZern, Mikkael A. Sekeres, Rami S. Komrokji, Nancy Gillis, Eric Padron

Blood (2024) 144 (Supplement 1): 354.

https://doi.org/10.1182/blood-2024-203837

Published: 2024

Journal Articles

Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

Luca Lanino, Saverio D'Amico, Giulia Maggioni, Najla H. Al Ali, Yu-Hung Wang, Carmelo Gurnari, Nico Gagelmann, Jan Philipp Bewersdorf, Somedeb Ball, Paola Guglielmelli, Manja Meggendorfer, Anthony M. Hunter, Anne Sophie Kubasch, Erica Travaglino, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Cristina Astrid Tentori, Alessandro Buizza, Elisabetta Sauta, Matteo Zampini, Elena Riva, Gianluca Asti, Mattia Delleani, Francesca Ficara, Armando Santoro, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Tariq Kewan, Ilaria Carola Casetti, Hussein Awada, Blanca Xicoy, Vladan Vucinic, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Angela Consagra, David Sallman, Wolfgang Kern, Massimo Bernardi, Patrizia Chiusolo, Lorenza Maria Borin, Maria Teresa Voso, Lisa Pleyer, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Guillermo Garcia-Manero, Sanam Loghavi, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Nicolaus Kröger, Pierre Fenaux, Michaela Fontenay, Valeria Santini, Torsten Haferlach, Ulrich Germing, Eric Padron, Marie Robin, Francesco Passamonti, Eric Solary, Alessandro M. Vannucchi, Gastone Castellani, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2024-204826

Published: 2024

Journal Articles

CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?

Rami S. Komrokji, Zena Komrokji, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Joseph E. Jabbour, Alison R. Walker, Jeffrey E Lancet, David Sallman, Eric Padron

Blood (2024) 144 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2024-205451

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Fatima Tuz Zahra, Faustine Ong, Moazzam Shahzad, Onyee Chan, Najla H. Al Ali, Jeffrey E Lancet, Alison R. Walker, David Sallman, Rami S. Komrokji, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie

Blood (2024) 144 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2024-211740

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

Journal Articles

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew T. Kuykendall, David Sallman, Manish Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2024-198495

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Ziad Abuhelwa, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 4589.

https://doi.org/10.1182/blood-2024-204064

Published: 2024

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2024-210646

Published: 2024

Journal Articles

Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience

Fatima Tuz Zahra, Faustine Ong, Daniel Walgenbach, Onyee Chan, Katherine Tobon, Jeffrey E Lancet, David Sallman, Rami S. Komrokji, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Zhuoer Xie, Seongseok Yun

Blood (2024) 144 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2024-202576

Published: 2024

Journal Articles

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Jeremy V. DiGennaro, Dimitrios Drekolias, Najla H. Al Ali, Onyee Chan, Seongseok Yun, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, Rami S. Komrokji, David Sallman

Blood (2024) 144 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2024-208927

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only